VIDEO: ReNetX Bio’s neuroprotection technology promising for glaucoma treatment

ByJames C. Tsai, MD, MBA

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SAN FRANCISCO — At the Glaucoma 360: New Horizons Forum, James C. Tsai, MD, MBA, president of New York Eye and Ear Infirmary of Mount Sinai and chair of the department of ophthalmology at Icahn School of Medicine at Mount Sinai, discusses neuroprotection technology from ReNetX Bio for glaucoma. The new biologic protein enhances regeneration of dead or damaged retinal ganglion cells, he said.